Page 80 - GTM-1-1

Global Translational Medicine ctDNA in management of patients with NSCLC

https://doi.org/10.1186/s12943-021-01323-9 concomitant Atezolizumab in patients with stage I (Tumors
≥ 4cm), IIA, IIB, and select IIIA (T3N1-2, T4N0-2) resected
58. Zviran A, Schulman RC, Shah M, et al., 2020, Genome-wide
cell-free DNA mutational integration enables ultra-sensitive non-small cell lung cancer (NSCLC) and the clearance of
cancer monitoring. Nat Med, 26(7): 1114–1124. circulating tumor DNA (ctDNA) (the BTCRC-LUN19-396
Trial). Available from: https://www.clinicaltrials.gov/ct2/
https://doi.org/10.1038/s41591-020-0915-3 show/NCT04367311. [Last accessed on 2021 Jun 30].
59. Henriksen TV, Tarazona N, Frydendahl A, et al., 2022, 69. Adjuvant durvalumab for early stage NSCLC patients with
Circulating tumor DNA in stage III colorectal cancer, ctDNA minimal residual disease. Available from: https://
beyond minimal residual disease detection, toward www.clinicaltrials.gov/ct2/show/NCT04585477 [Last
assessment of adjuvant therapy efficacy and clinical behavior accessed on 2021 Jun 30].
of recurrences. Clin Cancer Res, 28(3): 507–517.
70. Personalized escalation of consolidation treatment
60. Ettinger DS, Wood DE, Aisner DL, et al., 2021, following chemoradiotherapy and immunotherapy in stage
NCCN guidelines insights: non-small cell lung cancer, III NSCLC in stage III NSCLC. Available from: https://www.
version 2.2021. J Natl Compr Canc Netw, 19(3): 254–266. clinicaltrials.gov/ct2/show/NCT04585490 [Last accessed on
https://doi.org/10.6004/jnccn.2021.0013 2021 Jun 30].
71. Circulating tumor DNA (ctDNA) for early treatment
61. Passiglia F, Bertaglia V, Reale ML, et al., 2021, Major
breakthroughs in lung cancer adjuvant treatment: Looking response assessment of solid tumors. Available from: https://
beyond the horizon. Cancer Treat Rev, 101: 102308. www.clinicaltrials.gov/ct2/show/NCT04354064 [Last
accessed on 2021 Jun 30].
https://doi.org/10.1016/j.ctrv.2021.102308
72. A study of the efficacy and safety of RO7198457 in
62. Wu YL, Zhou C, Liam CK, et al., 2015, First-line erlotinib combination with atezolizumab versus atezolizumab
versus gemcitabine/cisplatin in patients with advanced alone following adjuvant platinum-doublet chemotherapy
EGFR mutation-positive non-small-cell lung cancer: in participants who are ctDNA positive after surgical
Analyses from the phase III, randomized, open-label, resection of stage II-III non-small cell lung cancer. Available
ENSURE study. Ann Oncol, 26(9): 1883–1889. from: https://www.clinicaltrials.gov/ct2/show/record/
https://doi.org/10.1093/annonc/mdv270 NCT04267237 [Last accessed on 2021 Jun 30].
73. A study evaluating the efficacy and safety of adjuvant
63. Goss G, Tsai CM, Shepherd FA, et al., 2016, Osimertinib for
pretreated EGFR Thr790Met-positive advanced non-small- platinum-doublet chemotherapy, with or without
cell lung cancer (AURA2): A multicentre, open-label, single- atezolizumab, in patients who are ctDNA positive after
arm, phase 2 study. Lancet Oncol, 17(12): 1643–1652. complete surgical resection of stage IB to select IIIB non-
small cell lung cancer (CATHAYA). Available from: https://
https://doi.org/10.1016/S1470-2045(16)30508-3 www.clinicaltrials.gov/ct2/show/record/NCT04611776
64. Nabet BY, Esfahani MS, Moding EJ, et al., 2020, Noninvasive [Last accessed on 2021 Jun 30].
early identification of therapeutic benefit from immune 74. Horn L, Whisenant JG, Wakelee H, et al., 2019, Monitoring
checkpoint inhibition. Cell, 183(2): 363–376.e13. therapeutic response and resistance: Analysis of circulating
https://doi.org/10.1016/j.cell.2020.09.001 tumor DNA in patients with ALK+ lung cancer. J Thorac
Oncol, 14(11): 1901–1911.
65. Moding EJ, Liu Y, Nabet BY, et al., 2020, Circulating
tumor DNA dynamics predict benefit from consolidation https://doi.org/10.1016/j.jtho.2019.08.003
immunotherapy in locally advanced non-small cell lung 75. Gao Z, Shang Y, Wang X, et al., 2019, Application of
cancer. Nat Cancer, 1(2): 176–183. circulating tumor DNA for dynamic monitoring of advanced
https://doi.org/10.1038/s43018-019-0011-0 non-small cell lung cancer treatment response: An open-
label, multicenter, prospective, observational study protocol.
66. Phase III study to determine the efficacy of durvalumab in Thorac Cancer, 10(5): 1310–1315.
combination with chemotherapy in completely resected stage
II-III non-small cell lung cancer (NSCLC) (the MERMAID-1 https://doi.org/10.1111 / 1759-7714.13031
Trial). Available from: https://wwwclinicaltrialsgov/ct2/ 76. Qiu B, Guo W, Zhang F, et al., 2021, Dynamic recurrence risk
show/NCT04385368 [Last accessed on 2021 Jun 30]. and adjuvant chemotherapy benefit prediction by ctDNA in
67. Phase III study to determine efficacy of durvalumab in stage resected NSCLC. Nat Commun, 12(1): 6770.
II-III non-small cell lung cancer (NSCLC) after curative https://doi.org/10.1038/s41467-021-27022-z
intent therapy (the MERMAID-2 Trial). Available from: 77. Kang G, Chen K, Yang F, et al., 2019, Monitoring of
https://wwwclinicaltrialsgov/ct2/show/NCT04642469 [Last circulating tumor DNA and its aberrant methylation in the
accessed on 2021 Jun 30].
surveillance of surgical lung Cancer patients: Protocol for a
68. Adjuvant treatment with cisplatin-based chemotherapy plus prospective observational study. BMC Cancer,19(1): 579.

Volume 1 Issue 1 (2022) 13 https://doi.org/10.36922/gtm.v1i1.96